← Back to screener

NEKTAR THERAPEUTICS NKTR

Rank #2454 · Nasdaq · $1.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
16.8
P/E
-11.0
P/B
10.03
ROE
-90.8%
Op. Margin
-106.9%
Debt Ratio
186%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -11.0x, P/B 10.03x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -90.8%. Ranks in the top 92% of the universe.

Safety ★★☆☆☆
Average

Debt ratio 186%. Ranks in the top 60% of the universe.

Growth ★★★☆☆
Good

Revenue growth of 9.2% year over year. Ranks in the top 37% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.1B$-0.1B$-0.1B$0.2B-132.3226
2012$0.2B$-0.0B$-0.0B$0.1B-17.8399
2013$0.1B$-0.1B$-0.1B$0.1B-173.4497
2014$0.1B$-0.1B$-0.2B$0.2B-173.9265
2015$0.1B$-0.1B$-0.2B$0.0B-80.7862
2016$0.2B$-0.0B$-0.1B$-0.1B-8.2-547
2017$0.2B$-0.0B$-0.1B$0.0B-12.71323
2018$0.2B$-0.1B$-0.2B$0.0B-68.26549
2019$0.3B$-0.1B$-0.1B$0.1B-19.4491
2020$1.2B$0.7B$0.7B$0.1B57.6651
2021$0.1B$-0.4B$-0.4B$1.7B-383.927
2022$0.2B$-0.4B$-0.4B$1.4B-278.031
2023$0.1B$-0.4B$-0.5B$1.1B-437.832
2024$0.1B$-0.3B$-0.3B$0.4B-292.673
2025$0.1B$-0.1B$-0.1B$0.1B-106.9186

← See the full screener